

# Stefan Leucht

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4757850/stefan-leucht-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

417  
papers

31,200  
citations

87  
h-index

169  
g-index

484  
ext. papers

37,675  
ext. citations

6.9  
avg, IF

7.31  
L-index

#	Paper	IF	Citations
4 <sup>17</sup>	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet, The</i> , <b>2013</b> , 382, 951-62	40	1665
4 <sup>16</sup>	Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. <i>Lancet, The</i> , <b>2009</b> , 373, 31-41	40	1385
4 <sup>15</sup>	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , <b>2011</b> , 10, 52-77	14.4	1288
4 <sup>14</sup>	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. <i>Lancet, The</i> , <b>2018</b> , 391, 1357-1366	40	1283
4 <sup>13</sup>	What does the PANSS mean?. <i>Schizophrenia Research</i> , <b>2005</b> , 79, 231-8	3.6	889
4 <sup>12</sup>	Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. <i>Schizophrenia Research</i> , <b>1999</b> , 35, 51-68	3.6	696
4 <sup>11</sup>	Clinical implications of Brief Psychiatric Rating Scale scores. <i>British Journal of Psychiatry</i> , <b>2005</b> , 187, 366-374	3.4	667
4 <sup>10</sup>	Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. <i>Lancet, The</i> , <b>2012</b> , 379, 2063-71	40	574
4 <sup>09</sup>	Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 414-25	11.9	566
4 <sup>08</sup>	Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. <i>Lancet, The</i> , <b>2019</b> , 394, 939-951	40	504
4 <sup>07</sup>	New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. <i>Lancet, The</i> , <b>2003</b> , 361, 1581-9	40	500
4 <sup>06</sup>	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , <b>2011</b> , 10, 138-51	14.4	489
4 <sup>05</sup>	Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. <i>Schizophrenia Research</i> , <b>2010</b> , 123, 225-33	3.6	481
4 <sup>04</sup>	Physical illness and schizophrenia: a review of the literature. <i>Acta Psychiatrica Scandinavica</i> , <b>2007</b> , 116, 317-33	6.5	444
4 <sup>03</sup>	The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2001</b> , 27, 73-92	1.3	426
4 <sup>02</sup>	A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. <i>American Journal of Psychiatry</i> , <b>2009</b> , 166, 152-63	11.9	389
4 <sup>01</sup>	Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 1209-22	11.9	365

400	How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. <i>Molecular Psychiatry</i> , <b>2009</b> , 14, 429-47	15.1	347
399	Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. <i>Lancet, The</i> , <b>2016</b> , 388, 881-90	4.0	343
398	Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. <i>American Journal of Psychiatry</i> , <b>2002</b> , 159, 180-90	11.9	334
397	Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 185-94	11.9	322
396	Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. <i>Schizophrenia Research</i> , <b>2011</b> , 127, 83-92	3.6	318
395	Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 443-57	1.3	301
394	Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 192-213	1.3	281
393	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. <i>British Journal of Psychiatry</i> , <b>2012</b> , 200, 97-106	5.4	257
392	Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 181-91	1.3	240
391	Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 927-942	11.9	227
390	Linking the PANSS, BPRS, and CGI: clinical implications. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 2318-25	8.7	223
389	Dose Equivalents for Antipsychotic Drugs: The DDD Method. <i>Schizophrenia Bulletin</i> , <b>2016</b> , 42 Suppl 1, S90-4	1.3	221
388	Shared decision making for in-patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2006</b> , 114, 265-73	6.5	220
387	Dose equivalents for second-generation antipsychotics: the minimum effective dose method. <i>Schizophrenia Bulletin</i> , <b>2014</b> , 40, 314-26	1.3	211
386	Living systematic review: 1. Introduction-the why, what, when, and how. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 23-30	5.7	211
385	Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry, the</i> , <b>2014</b> , 1, 351-9 <sup>23-3</sup>	20.7	207
384	Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. <i>Neuropsychopharmacology</i> , <b>2011</b> , 36, 375-89	8.7	202
383	Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. <i>Schizophrenia Bulletin</i> , <b>2012</b> , 38, 167-77	1.3	191

382	Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. <i>Biological Psychiatry</i> , <b>2005</b> , 57, 1543-9	7.9	190
381	Shared decision making in psychiatry. <i>Acta Psychiatrica Scandinavica</i> , <b>2003</b> , 107, 403-9	6.5	190
380	Standardized remission criteria in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2006</b> , 113, 91-5	6.5	189
379	Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. <i>Journal of Psychopharmacology</i> , <b>2008</b> , 22, 11-23	4.6	186
378	Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. <i>Journal of Affective Disorders</i> , <b>2015</b> , 180, 179-84	6.6	178
377	Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. <i>Archives of General Psychiatry</i> , <b>2007</b> , 64, 442-55		176
376	Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 706-15	14.5	174
375	Do patients with schizophrenia wish to be involved in decisions about their medical treatment?. <i>American Journal of Psychiatry</i> , <b>2005</b> , 162, 2382-4	11.9	172
374	Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 199-210	14.5	170
373	Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. <i>Acta Psychiatrica Scandinavica</i> , <b>2015</b> , 131, 185-96	6.5	160
372	Acamprosate for alcohol dependence. <i>The Cochrane Library</i> , <b>2010</b> , CD004332	5.2	160
371	Living systematic reviews: 2. Combining human and machine effort. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 31-37	5.7	156
370	Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. <i>Schizophrenia Bulletin</i> , <b>2007</b> , 33, 183-91	1.3	156
369	Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. <i>Acta Psychiatrica Scandinavica</i> , <b>2009</b> , 119, 7-14	6.5	146
368	Defining response in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. <i>Neuropsychopharmacology</i> , <b>2007</b> , 32, 1903-10	8.7	143
367	Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 376-85	5.5	139
366	Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. <i>Journal of Clinical Epidemiology</i> , <b>2004</b> , 57, 1124-30	5.7	135
365	Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 1742-51	8.7	134

364	Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. <i>Psychological Medicine</i> , <b>2009</b> , 39, 1591-602	6.9	132
363	Dropout rates in randomised antipsychotic drug trials. <i>Psychopharmacology</i> , <b>2001</b> , 155, 230-3	4.7	131
362	Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 1397-402	1.3	127
361	Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. <i>Schizophrenia Bulletin</i> , <b>2012</b> , 38, 1003-11	1.3	120
360	Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 876-86	11.9	115
359	Clozapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2010</b> , CD006633	5.2	115
358	What does the HAMD mean?. <i>Journal of Affective Disorders</i> , <b>2013</b> , 148, 243-8	6.6	114
357	Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. <i>Dialogues in Clinical Neuroscience</i> , <b>2010</b> , 12, 393-407	5.7	114
356	Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. <i>Lancet Psychiatry</i> , <b>2016</b> , 3, 1059-1066	23.3	112
355	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , <b>2015</b> , 172, 617-29	11.9	111
354	Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 1623-33	5.5	110
353	Attitudes of psychiatrists toward antipsychotic depot medication. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1948-53	4.6	110
352	Shared decision making and long-term outcome in schizophrenia treatment. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 992-7	4.6	110
351	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , <b>2017</b> , 16, 77-89	14.4	109
350	Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. <i>Biological Psychiatry</i> , <b>2011</b> , 69, 495-503	7.9	108
349	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , <b>2013</b> , 18, 53-66	15.1	105
348	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. <i>BMJ Open</i> , <b>2016</b> , 6, e010919	3	105
347	Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, 520-32	1.2	101

346	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. <i>Lancet Psychiatry, the</i> , <b>2018</b> , 5, 797-807	23.3	100
345	The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 406-12	8.7	100
344	Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. <i>Lancet Psychiatry, the</i> , <b>2016</b> , 3, 935-946	23.3	100
343	The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. <i>Journal of Clinical Psychiatry</i> , <b>2003</b> , 64 Suppl 12, 5-19 <sup>4.6</sup>	4.6	100
342	Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. <i>Lancet Psychiatry, the</i> , <b>2019</b> , 6, 601-609 <sup>3.3</sup>	3.3	99
341	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, 603-619 <sup>1.3</sup>	1.3	99
340	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. <i>JAMA Psychiatry</i> , <b>2017</b> , 74, 675-684	14.5	94
339	How to obtain NNT from Cohen's d: comparison of two methods. <i>PLoS ONE</i> , <b>2011</b> , 6, e19070	3.7	94
338	The concepts of remission and recovery in schizophrenia. <i>Pharmacopsychiatry</i> , <b>2006</b> , 39, 161-70	2	94
337	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , <b>2012</b> , CD008016 <sup>2</sup>	16	92
336	Early prediction of antipsychotic nonresponse among patients with schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 352-60	4.6	92
335	Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , <b>2018</b> , 16, 420-429	1.1	89
334	Second-generation antipsychotics and constipation: a review of the literature. <i>European Psychiatry</i> , <b>2011</b> , 26, 34-44	6	88
333	Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. <i>Depression and Anxiety</i> , <b>2009</b> , 26, 922-9	8.4	88
332	Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75 Suppl 1, 8-14	4.6	87
331	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2010</b> , CD006654 <sup>2</sup>	5.2	87
330	Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2018</b> , 268, 625-639	5.1	86
329	Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. <i>Schizophrenia Research</i> , <b>2008</b> , 98, 318-22	3.6	86

328	Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. <i>Clinica Chimica Acta</i> , <b>2001</b> , 308, 33-41	6.2	84
327	Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. <i>Pharmacogenomics Journal</i> , <b>2010</b> , 10, 20-9	3.5	83
326	Equipercntile linking of the BPRS and the PANSS. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 956-9	1.2	81
325	Living systematic reviews: 4. Living guideline recommendations. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 47-53	5.7	81
324	Opioid antagonists for alcohol dependence. <i>The Cochrane Library</i> , <b>2010</b> ,	5.2	80
323	17.1 PREDICTORS OF RELAPSE IN FIRST EPISODE PSYCHOSIS PATIENTS IN REMISSION. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, S115-S116	1.3	78
322	17.4 STRATIFICATION AND PREDICTION OF REMISSION IN FIRST-EPISODE PSYCHOSIS PATIENTS: THE OPTIMISE COHORT STUDY. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, S116-S117	1.3	78
321	T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS [PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, S308-S308	1.3	78
320	META-ANALYSES ON DOUBLE-BLIND RCTS ADDING DRUGS WITH ANTI-INFLAMMATORY PROPERTIES TO ANTIPSYCHOTIC MEDICATION. <i>Schizophrenia Research</i> , <b>2014</b> , 153, S15-S16	3.6	78
319	M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA [A META-REGRESSION ANALYSIS. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, S212-S213	1.3	78
318	Clozapine versus quetiapine for people with schizophrenia. <i>The Cochrane Library</i> , <b>2018</b> ,	5.2	78
317	Clozapine versus risperidone for people with schizophrenia. <i>The Cochrane Library</i> , <b>2018</b> ,	5.2	78
316	S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT). <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S342-S342	1.3	78
315	Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. <i>Evidence-Based Mental Health</i> , <b>2014</b> , 17, 33-7	11.1	77
314	The attitude of patients towards antipsychotic depot treatment. <i>International Clinical Psychopharmacology</i> , <b>2007</b> , 22, 275-82	2.2	75
313	Living systematic reviews: 3. Statistical methods for updating meta-analyses. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 91, 38-46	5.7	74
312	The Longitudinal Course of Schizophrenia Across the Lifespan: Clinical, Cognitive, and Neurobiological Aspects. <i>Harvard Review of Psychiatry</i> , <b>2016</b> , 24, 118-28	4.1	73
311	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , <b>2018</b> , 17, 330-340	14.4	73

310	Evidence-based pharmacotherapy of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , <b>2011</b> , 14, 269-84	5.8	72
309	Auditory hallucinations across the lifespan: a systematic review and meta-analysis. <i>Psychological Medicine</i> , <b>2018</b> , 48, 879-888	6.9	71
308	Combining randomized and non-randomized evidence in network meta-analysis. <i>Statistics in Medicine</i> , <b>2017</b> , 36, 1210-1226	2.3	70
307	Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 14-21	14.5	69
306	Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 17	3	69
305	Personality disorders and violence. <i>Current Opinion in Psychiatry</i> , <b>2008</b> , 21, 84-92	4.9	69
304	Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 694-705	23.3	66
303	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 342-353	11.9	65
302	Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. <i>World Psychiatry</i> , <b>2018</b> , 17, 316-329	14.4	64
301	Methodological issues in current antipsychotic drug trials. <i>Schizophrenia Bulletin</i> , <b>2008</b> , 34, 275-85	1.3	63
300	"How to speak to your psychiatrist": shared decision-making training for inpatients with schizophrenia. <i>Psychiatric Services</i> , <b>2011</b> , 62, 1218-21	3.3	62
299	Correlation between amygdala volume and age in bipolar disorder - a systematic review and meta-analysis of structural MRI studies. <i>Psychiatry Research - Neuroimaging</i> , <b>2010</b> , 182, 1-8	2.9	62
298	Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. <i>Schizophrenia Research</i> , <b>2005</b> , 80, 85-97	3.6	60
297	Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. <i>Schizophrenia Research</i> , <b>2004</b> , 70, 33-7	3.6	60
296	Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 659-674	1.2	59
295	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , <b>2020</b> , 7, 581-601	23.3	58
294	Risperidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2011</b> , CD006626	2.2	58
293	How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2017</b> , 27, 835-844	1.2	57



292	The clinical significance of cognition-focused interventions for cognitively impaired older adults: a systematic review of randomized controlled trials. <i>International Psychogeriatrics</i> , <b>2011</b> , 23, 1364-75	3.4	57
291	Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. <i>Schizophrenia Bulletin</i> , <b>2009</b> , 35, 789-97	1.3	57
290	Accuracy and reproducibility of the measurement of actively circulating blood volume with an integrated fiberoptic monitoring system. <i>Critical Care Medicine</i> , <b>1995</b> , 23, 885-93	1.4	57
289	Benzodiazepines for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2007</b> , CD006391		56
288	How effective are common medications: a perspective based on meta-analyses of major drugs. <i>BMC Medicine</i> , <b>2015</b> , 13, 253	11.4	52
287	Second-generation antipsychotics for major depressive disorder and dysthymia. <i>The Cochrane Library</i> , <b>2010</b> , CD008121	5.2	52
286	Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. <i>Pharmacogenomics</i> , <b>2006</b> , 7, 159-66	2.6	52
285	Caregivers of patients with frontotemporal lobar degeneration: a review of burden, problems, needs, and interventions. <i>International Psychogeriatrics</i> , <b>2012</b> , 24, 1368-86	3.4	51
284	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2009</b> , CD006569		51
283	ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. <i>Clinical Chemistry</i> , <b>2006</b> , 52, 893-5	5.5	51
282	Lithium for Schizophrenia Revisited. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 177-186	4.6	51
281	Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67, 1813-4	4.6	51
280	Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies. <i>Biological Psychiatry</i> , <b>2019</b> , 85, 573-583	7.9	51
279	Lithium for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2007</b> , CD003834		49
278	Psychiatrists' Attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. <i>European Psychiatry</i> , <b>2011</b> , 26, 297-301	6	48
277	The PANSS should be rescaled. <i>Schizophrenia Bulletin</i> , <b>2010</b> , 36, 461-2	1.3	48
276	Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. <i>Biological Psychiatry</i> , <b>2010</b> , 68, 86-92	7.9	48
275	Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. <i>Schizophrenia Research</i> , <b>2008</b> , 101, 312-9	3.6	46

274	Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 1023-33 <sup>1,2</sup>	44
273	Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. <i>Evidence-Based Mental Health</i> , <b>2017</b> , 20, 88-94	11.1 44
272	Addressing missing outcome data in meta-analysis. <i>Evidence-Based Mental Health</i> , <b>2014</b> , 17, 85-9	11.1 44
271	On the concept of remission in schizophrenia. <i>Psychopharmacology</i> , <b>2007</b> , 194, 453-61	4.7 42
270	Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. <i>Lancet Psychiatry</i> , <b>2018</b> , 5, 653-663 <sup>23,3</sup>	42
269	Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. <i>The Cochrane Library</i> , <b>2015</b> , 1, CD009831	5.2 41
268	How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, 639-646	1.3 41
267	Quetiapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2013</b> , CD006625	5.2 41
266	Valproate for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2008</b> , CD004028	41
265	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2014</b> , CD006569	5.2 40
264	Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials. <i>Schizophrenia Research</i> , <b>2016</b> , 178, 17-22	3.6 39
263	The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 549-58	1.3 38
262	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , <b>2013</b> , 150, 328-33	3.6 38
261	Antidepressants for the negative symptoms of schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2006</b> , CD005581	38
260	Medical decision making in antipsychotic drug choice for schizophrenia. <i>American Journal of Psychiatry</i> , <b>2004</b> , 161, 1301-4	11.9 38
259	Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. <i>International Journal of Neuropsychopharmacology</i> , <b>2004</b> , 7 Suppl 1, S15-20	5.8 38
258	Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 395-403	3.5 37
257	Second-generation antipsychotics for obsessive compulsive disorder. <i>The Cochrane Library</i> , <b>2010</b> , CD008341	4.1 36

256	Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses. <i>Psychological Medicine</i> , <b>2011</b> , 41, 2651-9	6.9	36
255	Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1616-27	4.6	36
254	How to read and understand and use systematic reviews and meta-analyses. <i>Acta Psychiatrica Scandinavica</i> , <b>2009</b> , 119, 443-50	6.5	35
253	Haloperidol versus chlorpromazine for schizophrenia. <i>The Cochrane Library</i> , <b>2008</b> , CD004278	5.2	35
252	Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination. <i>BMC Medicine</i> , <b>2015</b> , 13, 82	11.4	34
251	Equipercetile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1767-72	1.2	34
250	Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. <i>Clinical Trials</i> , <b>2013</b> , 10, 378-88	2.2	34
249	MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?. <i>International Journal of Neuropsychopharmacology</i> , <b>2013</b> , 16, 2103-9	5.8	33
248	Second-generation antipsychotics for anxiety disorders. <i>The Cochrane Library</i> , <b>2010</b> , CD008120	5.2	33
247	Ziprasidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2009</b> , CD006623	3.2	33
246	Quetiapine versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2010</b> , CD006625		33
245	Comparative remission rates of schizophrenic patients using various remission criteria. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 1643-51	5.5	33
244	Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 32-45	1.2	33
243	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 270-280	14.5	33
242	Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders: A Meta-analysis. <i>JAMA Psychiatry</i> , <b>2019</b> , 76, 1063-1073	14.5	32
241	Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. <i>Brain</i> , <b>2019</b> , 142, 1813-1826	11.2	32
240	Benzodiazepines for schizophrenia. <i>The Cochrane Library</i> , <b>2012</b> , 11, CD006391	5.2	32
239	Amisulpride is an "atypical" antipsychotic associated with low weight gain. <i>Psychopharmacology</i> , <b>2004</b> , 173, 112-5	4.7	32

238	Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 138, 281-288	6.5	32
237	Carbamazepine augmentation for schizophrenia: how good is the evidence?. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 218-24	4.6	31
236	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 20	8.6	30
235	Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. <i>Schizophrenia Research</i> , <b>2013</b> , 145, 125-7	3.6	30
234	An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 2275-87	2.3	30
233	Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , <b>2018</b> , 137, 450-458	6.5	29
232	Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention. <i>Schizophrenia Bulletin</i> , <b>2015</b> , 41, 584-96	1.3	28
231	A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation. <i>Acta Psychiatrica Scandinavica</i> , <b>2014</b> , 130, 326-41	6.5	28
230	Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain. <i>Journal of Clinical Psychopharmacology</i> , <b>2013</b> , 33, 74-9	1.7	28
229	Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. <i>Psychopharmacology</i> , <b>2000</b> , 147, 378-83	4.7	28
228	Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review. <i>Journal of Alzheimers Disease</i> , <b>2017</b> , 55, 1583-1594	4.3	28
227	What does the MADRS mean? Equipercetile linking with the CGI using a company database of mirtazapine studies. <i>Journal of Affective Disorders</i> , <b>2017</b> , 210, 287-293	6.6	27
226	Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. <i>Genetic Testing and Molecular Biomarkers</i> , <b>2014</b> , 18, 20-31	1.6	26
225	The Prevalence of Mental Illness in Homeless People in Germany. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2017</b> , 114, 665-672	2.5	26
224	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , <b>2021</b> , 8, 969-980	23.3	26
223	Maximizing response to first-line antipsychotics in schizophrenia: a review focused on findings from meta-analysis. <i>Psychopharmacology</i> , <b>2019</b> , 236, 545-559	4.7	26
222	Translating the HAM-D into the MADRS and vice versa with equipercetile linking. <i>Journal of Affective Disorders</i> , <b>2018</b> , 226, 326-331	6.6	25
221	Amitriptyline versus placebo for major depressive disorder. <i>The Cochrane Library</i> , <b>2012</b> , 12, CD009138	5.2	25

220	DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 71-7	3.5	25
219	Carbamazepine for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2007</b> , CD001258		25
218	Physical Illness and Schizophrenia: A Review of the Evidence <b>2007</b> ,		25
217	Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 1003-1022	1.2	24
216	Do antipsychotic drugs lose their efficacy for relapse prevention over time?. <i>British Journal of Psychiatry</i> , <b>2017</b> , 211, 127-129	5.4	24
215	Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 387-94	4.6	24
214	CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 152-60	3.2	23
213	Valproate for schizophrenia. <i>The Cochrane Library</i> , <b>2016</b> , 11, CD004028	5.2	23
212	The deceleration capacity - a new measure of heart rate variability evaluated in patients with schizophrenia and antipsychotic treatment. <i>European Psychiatry</i> , <b>2013</b> , 28, 81-6	6	22
211	Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms. <i>Schizophrenia Research</i> , <b>2015</b> , 162, 169-74	3.6	22
210	Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. <i>Schizophrenia Research</i> , <b>2011</b> , 126, 212-9	3.6	22
209	Identifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2008</b> , 32, 1987-93	5.5	22
208	Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. <i>Schizophrenia Research</i> , <b>2018</b> , 193, 23-28	3.6	21
207	Lithium for schizophrenia. <i>The Cochrane Library</i> , <b>2015</b> , CD003834	5.2	21
206	Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. <i>Pharmacopsychiatry</i> , <b>2003</b> , 36, 18-26	2	21
205	Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. <i>Evidence-Based Mental Health</i> , <b>2018</b> , 21, 1-3	11.1	20
204	Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 859-867	23.3	20
203	Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 501-5	1.2	20

202	Amisulpride versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2010</b> , CD006624	4.2	20
201	Doxepin plasma concentrations: is there really a therapeutic range?. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 432-9	1.7	20
200	Translating the BDI and BDI-II into the HAMD and vice versa with equipercetile linking. <i>Epidemiology and Psychiatric Sciences</i> , <b>2019</b> , 29, e24	5.1	20
199	Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices. <i>International Clinical Psychopharmacology</i> , <b>2014</b> , 29, 224-8 <sup>2</sup>	3.2	19
198	Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia. <i>Schizophrenia Research</i> , <b>2012</b> , 141, 168-72	3.6	19
197	How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?. <i>European Neuropsychopharmacology</i> , <b>2010</b> , 20, 276-9	1.2	18
196	Unanswered questions in schizophrenia clinical trials. <i>Schizophrenia Bulletin</i> , <b>2008</b> , 34, 302-9	1.3	18
195	Perphenazine for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2005</b> , CD003443		18
194	Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 1360-1370	1.2	18
193	Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, 1046-55	1.2	17
192	Psychiatric treatment guidelines: doctors non-compliance or insufficient evidence?. <i>Acta Psychiatrica Scandinavica</i> , <b>2007</b> , 115, 417-9	6.5	17
191	60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response. <i>Schizophrenia Research</i> , <b>2018</b> , 201, 315-323	3.6	17
190	Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. <i>Schizophrenia Research</i> , <b>2014</b> , 156, 107-14	3.6	16
189	Imputation of response rates from means and standard deviations in schizophrenia. <i>Schizophrenia Research</i> , <b>2013</b> , 151, 209-14	3.6	16
188	Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1589-1596	8.7	15
187	Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , <b>2019</b> , 6, 753-765	23.3	15
186	Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 1051-6	1.2	15
185	Clinical relevance of findings in trials of CBT for depression. <i>European Psychiatry</i> , <b>2017</b> , 45, 207-211	6	15

184	Results of treatment of schizophrenia: is the glass half full or half empty?. <i>International Clinical Psychopharmacology</i> , <b>1999</b> , 14 Suppl 3, S11-4	2.2	15
183	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. <i>Molecular Autism</i> , <b>2020</b> , 11, 66	6.5	15
182	Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. <i>European Psychiatry</i> , <b>2016</b> , 32, 16-20	6	14
181	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2013</b> , CD006569		14
180	Psychiatrists' decision making between branded and generic drugs. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 686-90	1.2	14
179	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , <b>2020</b> , 8, CD008016	9.1	14
178	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 34, 76-86	1.2	14
177	Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant. <i>Journal of Clinical Epidemiology</i> , <b>2016</b> , 69, 161-9	5.7	13
176	The controversy about cognitive behavioural therapy for schizophrenia. <i>World Psychiatry</i> , <b>2019</b> , 18, 235-244	2.6	13
175	Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 5-22	2.6	13
174	Monitoring of right ventricular function using a conventional slow response thermistor catheter. <i>Intensive Care Medicine</i> , <b>1994</b> , 20, 348-53	14.5	13
173	Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , <b>2018</b> , 18, 380	4.2	13
172	Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. <i>Lancet, The</i> , <b>2017</b> , 389, 1077-1078	1.2	12
171	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, 1439-1458	1.3	12
170	How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , <b>2020</b> , 20, 102	4.2	12
169	Antidepressants might work for people with major depression: where do we go from here?. <i>Lancet Psychiatry</i> , <b>2018</b> , 5, 461-463	23.3	12
168	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , <b>2014</b> , CD009268	5.2	12
167	Carbamazepine for schizophrenia. <i>The Cochrane Library</i> , <b>2014</b> , CD001258	5.2	12

166	Sertindole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2009</b> , CD006752	5.2	12
165	European psychiatric treatment guidelines: is the glass half full or half empty?. <i>European Psychiatry</i> , <b>2005</b> , 20, 554-8	6	12
164	Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review. <i>BMC Research Notes</i> , <b>2016</b> , 9, 218	2.3	11
163	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , <b>2014</b> , CD009230	5.2	11
162	Attaining and sustaining remission of predominant negative symptoms. <i>Schizophrenia Research</i> , <b>2013</b> , 143, 60-4	3.6	11
161	Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. <i>BMJ Open</i> , <b>2017</b> , 7, e016608	3	11
160	Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2017</b> , 267, 187-198	5.1	11
159	Psychiatric decision making in the adoption of a new antipsychotic in Germany. <i>Psychiatric Services</i> , <b>2006</b> , 57, 700-3	3.3	11
158	Language bias in neuroscience--is the Tower of Babel located in Germany?. <i>European Psychiatry</i> , <b>2004</b> , 19, 230-2	6	11
157	How do psychiatrists choose among different antipsychotics?. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 851-4	2.8	11
156	Physicians and patients' involvement in relapse prevention with antipsychotics in schizophrenia. <i>Psychiatric Services</i> , <b>2005</b> , 56, 1448-50	3.3	11
155	Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. <i>Lancet, The</i> , <b>2022</b> , 399, 824-836	4.0	11
154	The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 1010-6	1.2	10
153	Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 812-7	1.2	10
152	Haloperidol versus first generation antipsychotics for schizophrenia <b>2012</b> ,		10
151	Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1955-1966	8.7	9
150	Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , <b>2014</b> , CD009396	5.2	9
149	Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. <i>Schizophrenia Bulletin</i> , <b>2020</b> , 46, 496-504	1.3	8



148	Flupenthixol versus low-potency first generation antipsychotic drugs for schizophrenia <b>2011</b> ,		8
147	Zotepine versus other atypical antipsychotics for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , <b>2010</b> , CD006628		8
146	Haloperidol versus chlorpromazine for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , <b>2008</b> , 34, 813-53		8
145	Cochrane Schizophrenia Group. <i>Schizophrenia Bulletin</i> , <b>2008</b> , 34, 259-65	1.3	8
144	Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?. <i>World Psychiatry</i> , <b>2018</b> , 17, 166-167	14.4	8
143	Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 177-86	4.6	8
142	Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. <i>Schizophrenia Research</i> , <b>2015</b> , 164, 122-6	3.6	7
141	Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia <b>2011</b> ,		7
140	Variability of cerebral blood flow deficits in 99mTc-HMPAO SPECT in patients with Alzheimer's disease. <i>Journal of Neural Transmission</i> , <b>1997</b> , 104, 689-701	4.3	7
139	Commentary on strategies for switching antipsychotics. <i>BMC Medicine</i> , <b>2008</b> , 6, 18	11.4	7
138	Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 487	8.6	7
137	Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial. <i>Contemporary Clinical Trials Communications</i> , <b>2020</b> , 17, 100537	1.8	6
136	Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , <b>2018</b> , 8, e019280	3	6
135	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , <b>2018</b> , 5, CD011883.2		6
134	Clozapine resistance--augmentation strategies. <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 338	1.2	6
133	Perphenazine for schizophrenia. <i>The Cochrane Library</i> , <b>2015</b> , CD003443	5.2	6
132	Patients' acceptance of the deltoid application of risperidone long-acting injection. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 897-901	1.2	6
131	Are patients with schizophrenia under-treated with second-generation antipsychotics? A pilot study of the prescription practices of German psychiatrists. <i>Pharmacopsychiatry</i> , <b>2003</b> , 36, 309-12	2	6

130	Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , <b>2020</b> , 18, 443-455	1.1	6
129	Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia. <i>Brain</i> , <b>2020</b> , 143, 3495-3505	11.2	5
128	Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , <b>2014</b> , CD009369	5.2	5
127	Critical trial-related criteria in acute schizophrenia studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2012</b> , 262, 151-5	5.1	5
126	Efficacy of antipsychotic drugs for schizophrenia - AuthorsPreply. <i>Lancet, The</i> , <b>2013</b> , 382, 1874-5	40	5
125	Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia <b>2011</b> ,		5
124	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia <b>2011</b> ,		5
123	Trifluoperazine versus low-potency first generation antipsychotic drugs for schizophrenia <b>2011</b> ,		5
122	Zotepine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , <b>2010</b> , CD006628	5.2	5
121	Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia. <i>International Clinical Psychopharmacology</i> , <b>2006</b> , 21 Suppl 2, S1-10	2.2	5
120	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.. <i>JAMA Psychiatry</i> , <b>2022</b> ,	14.5	5
119	Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. <i>Evidence-Based Mental Health</i> , <b>2021</b> , 24, 56-61	11.1	5
118	Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. <i>Molecular Diagnosis and Therapy</i> , <b>2012</b> , 16, 93-8	4.5	5
117	Relationship between costs and symptoms in schizophrenia patients treated with antipsychotic medication: a review. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 756-65	4.6	5
116	Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain. <i>Pharmacopsychiatry</i> , <b>2019</b> , 52, 16-23	2	5
115	Antipsychotic drugs: from major tranquilizers to Neuroscience-based-Nomenclature. <i>Psychological Medicine</i> , <b>2021</b> , 51, 522-524	6.9	5
114	Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2021</b> , 271, 293-302	5.1	5
113	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends.. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2022</b> , 136, 104608	9	5

112	The SWITCH study: rationale and design of the trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2016</b> , 266, 513-21	5.1	4
111	Clozapine in treatment-resistant schizophrenia. <i>British Journal of Psychiatry</i> , <b>2017</b> , 210, 299	5.4	4
110	A novel approach to measuring response and remission in schizophrenia in clinical trials. <i>Schizophrenia Research</i> , <b>2017</b> , 190, 123-128	3.6	4
109	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. <i>The Cochrane Library</i> , <b>2018</b> , 5, CD011884	5.2	4
108	Accounting for uncertainty due to fast observation carried forward outcome imputation in a meta-analysis model. <i>Statistics in Medicine</i> , <b>2015</b> , 34, 742-52	2.3	4
107	Are new drugs for schizophrenia better than old ones? [AuthorsPreply. <i>Lancet, The</i> , <b>2009</b> , 373, 1249-1250	4.0	4
106	Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.. <i>Lancet Psychiatry,the</i> , <b>2022</b> ,	23.3	4
105	Medical decision making in the mental health field. <i>Psychiatric Services</i> , <b>2005</b> , 56, 221	3.3	4
104	CATIE findings revisited. <i>Psychiatric Services</i> , <b>2009</b> , 60, 125-6	3.3	4
103	Antipsychotic drugs barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , <b>2020</b> , 50, 2622-2633	6.9	4
102	Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 1238-1248	14.5	4
101	Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models. <i>BMC Medical Research Methodology</i> , <b>2019</b> , 19, 33	4.7	3
100	Second-generation antipsychotics and quality of life in schizophrenia. <i>Lancet Psychiatry,the</i> , <b>2016</b> , 3, 694-695	2.9	3
99	Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , <b>2014</b> , CD009227	5.2	3
98	Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?. <i>Acta Psychiatrica Scandinavica</i> , <b>2014</b> , 130, 40-5	6.5	3
97	Maintenance treatment with antipsychotic drugs for schizophrenia <b>2009</b> ,		3
96	New generation versus conventional antipsychotics. <i>Lancet, The</i> , <b>2003</b> , 362, 404-405	4.0	3
95	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2020</b> , 270, 83-94	5.1	3

94	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. <i>Schizophrenia Research</i> , <b>2020</b> , 223, 271-278	3.6	3
93	Optimal Dose of Selective Serotonin Reuptake Inhibitors, Venlafaxine, and Mirtazapine in Major Depression: A Systematic Review and Dose-Response Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , <b>2020</b> , 18, 211-219	1.1	3
92	Associations between individual antipsychotics and the risk of arrests and convictions of violent and other crime: a nationwide within-individual study of 74 925 persons. <i>Psychological Medicine</i> , <b>2021</b> , 1-9	6.9	3
91	The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study. <i>Schizophrenia Research</i> , <b>2021</b> , 231, 100-107	3.6	3
90	Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 688950	5.6	3
89	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , <b>2021</b> , 64, e7	6	3
88	Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions. <i>Schizophrenia Research</i> , <b>2021</b> , 228, 425-434	3.6	3
87	Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , <b>2021</b> , 10, 214	3	3
86	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.. <i>Molecular Autism</i> , <b>2022</b> , 13, 10	6.5	3
85	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art.. <i>Schizophrenia Research: Cognition</i> , <b>2022</b> , 29, 100249	2.8	3
84	Markov model for longitudinal studies with incomplete dichotomous outcomes. <i>Pharmaceutical Statistics</i> , <b>2017</b> , 16, 122-132	1	2
83	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMiSE trial. <i>Psychiatry Research</i> , <b>2020</b> , 289, 112970	9.9	2
82	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. <i>World Journal of Biological Psychiatry</i> , <b>2016</b> , 17, 210-20	3.8	2
81	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , <b>2015</b> ,	5.2	2
80	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. <i>The Cochrane Library</i> , <b>2015</b> ,	5.2	2
79	Ventajas y desventajas del tratamiento de combinaci3n con antipsic3ticos. Reuni3n ECNP Consensus, marzo de 2008, Niza. <i>Psiquiatria Biologica</i> , <b>2011</b> , 18, 55-67	0.2	2
78	Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia. <i>Evidence-Based Mental Health</i> , <b>2007</b> , 10, 112	11.1	2
77	Pretrial medication bias in randomized antipsychotic drug trials. <i>American Journal of Psychiatry</i> , <b>2007</b> , 164, 1266; author reply 1266-7	11.9	2

76	Issues in psychopharmacology. <i>Schizophrenia Bulletin</i> , <b>2008</b> , 34, 258	1.3	2
75	Clozapine versus other atypical antipsychotics for schizophrenia <b>2007</b> ,		2
74	Olanzapine versus other atypical antipsychotics for schizophrenia <b>2007</b> ,		2
73	Benperidol for schizophrenia. <i>The Cochrane Library</i> , <b>2005</b> , CD003083	5.2	2
72	Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. <i>European Neuropsychopharmacology</i> , <b>2022</b> , 57, 50-58	1.2	2
71	Behandlungsresistenz <b>2016</b> , 157-176		2
70	What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials. <i>Lancet Psychiatry</i> , <b>2020</b> , 7, 1004-1006	23.3	2
69	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , <b>2021</b> , 229, 3-11	3.6	2
68	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. <i>Schizophrenia Bulletin Open</i> ,	2.2	2
67	An efficient way to assess the effect of COVID-19 on mental health in the general population. <i>Lancet Psychiatry</i> , <b>2021</b> , 8, e14-e15	23.3	2
66	Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 2320-2329	8.7	2
65	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. <i>Brain Sciences</i> , <b>2021</b> , 11,	3.4	2
64	Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence. <i>BMJ Open</i> , <b>2020</b> , 10, e035073	3	2
63	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 672-681	1.3	2
62	Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 1601-1610	1.3	2
61	Antipsychotic combinations for schizophrenia		2
60	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , <b>2022</b> , 9, 291-306	23.3	2
59	DSM-III-R change in definition might have affected placebo response to antidepressants - Authors' reply. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 22-23	23.3	1

58	Optimal dosing of antidepressant drugs - AuthorsReply. <i>Lancet Psychiatry</i> , 2019, 6, 806-807	23.3	1
57	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 378-386	1.1	1
56	Perazine for schizophrenia. <i>The Cochrane Library</i> , 2014, CD002832	5.2	1
55	Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 192-204	1.1	1
54	Pharmakotherapie der therapieresistenten Schizophrenie. <i>PSYCH Up2date</i> , 2014, 8, 281-297	0.1	1
53	Evidence-based pharmacotherapy of schizophrenia 18-38		1
52	Second-generation antipsychotic drugs for anxiety disorders 2009,		1
51	Aripiprazole versus other atypical antipsychotics for schizophrenia 2007,		1
50	Amisulpride versus other atypical antipsychotics for schizophrenia 2007,		1
49	Perazine for schizophrenia. <i>Cochrane Database of Systematic Reviews</i> , 2006, CD002832		1
48	Dr. Correll and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2005, 162, 405-a-406	11.9	1
47	Examining side effect variation in antipsychotic treatment and schizophrenia spectrum disorders		1
46	Schizophrenien und andere psychotische Störungen 2009, 411-490		1
45	An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia. <i>Medical Psychiatry</i> , 2009, 164-173		1
44	Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient Perspectives. <i>Pharmacopsychiatry</i> , 2021, 54, 53-59	2	1
43	Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. <i>European Psychiatry</i> , 2021, 64, e16	6	1
42	Clozapine versus olanzapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018,	5.2	1
41	Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1651-1660	4	1

40	Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , <b>2021</b> , 237, 20-25	3.6	1
39	Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 815718	5	1
38	Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.. <i>Lancet Psychiatry</i> , <b>2022</b> , 9, 232-242	23.3	1
37	31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , <b>2018</b> , 44, S50-S51	1.3	0
36	Drowning in numbers-what psychiatrists mean when talking to patients about probabilities of risks and benefits of medication. <i>European Psychiatry</i> , <b>2011</b> , 26, 130-1	6	0
35	New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment.. <i>Schizophrenia Research</i> , <b>2021</b> , 239, 192-199	3.6	0
34	Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil.. <i>Journal of Psychiatric Research</i> , <b>2022</b> , 148, 159-164	5.2	0
33	About the issue of including or excluding studies from China in systematic reviews.. <i>Schizophrenia Research</i> , <b>2022</b> , 240, 162-163	3.6	0
32	Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. <i>Journal of Alzheimers Disease</i> , <b>2021</b> , 82, 1075-1084	4.3	0
31	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , <b>2021</b> , 47, 986-996	1.3	0
30	Antipsychotics for schizophrenia and substance misuse - AuthorsPreply. <i>Lancet, The</i> , <b>2020</b> , 395, 1903	40	
29	Use of Clozapine in Schizophrenia-Reply. <i>JAMA Psychiatry</i> , <b>2016</b> , 73, 1098-1099	14.5	
28	Pharmakotherapie der therapieresistenten Schizophrenie. <i>PSYCH Up2date</i> , <b>2019</b> , 13, 223-240	0.1	
27	Bipolar treatment efficacy - AuthorsPreply. <i>Lancet Psychiatry</i> , <b>2014</b> , 1, 418-9	23.3	
26	Can we inflate effect size and thus increase chances of producing "positive" results if we raise the baseline threshold in schizophrenia trials?. <i>Schizophrenia Research</i> , <b>2013</b> , 144, 105-8	3.6	
25	Wirksamkeit von Psychotherapie und Pharmakotherapie. <i>InFo Neurologie &amp; Psychiatrie</i> , <b>2015</b> , 17, 34-41		0
24	Antipsychotic drugs for relapse prevention in schizophrenia [AuthorsPreply. <i>Lancet, The</i> , <b>2012</b> , 380, 105640		0
23	Intramuscular haloperidol and olanzapine begin to reduce psychosis within 24 hours. <i>Evidence-Based Mental Health</i> , <b>2006</b> , 9, 9	11.1	

22	Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia. <i>Evidence-Based Mental Health</i> , <b>2007</b> , 10, 56	11.1
21	Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders. <i>Evidence-Based Mental Health</i> , <b>2007</b> , 10, 46	11.1
20	Dr. Hamann and Colleagues Reply. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 937-937	11.9
19	Eleven-year clinical outcome of schizophrenia in Bali. <i>Acta Psychiatrica Scandinavica</i> , <b>2006</b> , 114, 68; author reply 68-9	6.5
18	Is there a differential efficacy of new generation antipsychotic drugs?. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2005</b> , 9, 154-6	2.4
17	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe.. <i>Neuropsychiatric Disease and Treatment</i> , <b>2022</b> , 18, 201-219	3.1
16	Spätschizophrenie und chronische Schizophrenie im höheren Lebensalter <b>2009</b> , 199-219	
15	In Reply. <i>Deutsches Arzteblatt International</i> , <b>2018</b> , 115, 68-69	2.5
14	Schizophrenien und andere psychotische Störungen <b>2019</b> , 301-362.e7	
13	Schizophrenien und andere psychotische Störungen <b>2015</b> , 349-412	
12	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie <b>2016</b> , 1-18	
11	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie <b>2017</b> , 1321-1338	
10	Therapieresistente Schizophrenie (ICD-10 F2) <b>2009</b> , 117-130	
9	Spätschizophrenie und chronische Schizophrenie im höheren Lebensalter <b>2011</b> , 241-262	
8	Metabolic Adverse Effects Associated with Antipsychotic Medications <b>2011</b> , 577-597	
7	Schizophrenien und andere psychotische Störungen <b>2012</b> , 347-419	
6	Let us not rush back to odds ratios without a recommendation to convert them to interpretable measures. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 134, 172-173	5.7
5	Authors Preply. <i>British Journal of Psychiatry</i> , <b>2016</b> , 209, 171-2	5.4



4	How long do psychiatrists wait for response before they switch to another antipsychotic? <i>Psychopharmacology Bulletin</i> , <b>2007</b> , 40, 149-54	0.9
3	Relapse prevention in schizophrenia - AuthorsPreply.. <i>Lancet Psychiatry,the</i> , <b>2022</b> , 9, e14	23.3
2	Confidence of evidence should be considered in ranking of treatments in the network meta-analysis - AuthorsPreply.. <i>Lancet Psychiatry,the</i> , <b>2022</b> , 9, e16	23.3
1	What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Analyses of a Phase III Clinical Trial.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 816339	5